Inhibition of complement C1s by sutimlimab (SUT) in patients with cold agglutinin disease (CAD): results on efficacy and safety from the randomized, placebo-controlled phase 3 CADENZA study (NCT03347422)

被引：0

作者：

Roeth, A. ^{[1
]}

Berentsen, S. ^{[2
]}

Barcellini, W. ^{[3
]}

D'Sa, S. ^{[4
]}

Jilma, B. ^{[5
]}

Michel, M. ^{[6
]}

Weitz, I. C. ^{[7
]}

Yamaguchi, M. ^{[8
]}

Nishimura, J. -i ^{[9
]}

Vos, J. M. ^{[10
,11
]}

Storek, M. ^{[12
]}

Wong, N. W. ^{[12
]}

Patel, P. ^{[12
]}

Jiang, X. ^{[12
]}

Vagge, D. ^{[13
]}

Wardecki, M. ^{[14
]}

Shafer, F. ^{[12
]}

Lee, M. ^{[12
]}

Broome, C. M. ^{[15
]}

机构：

[1] Univ Hosp Essen, Dept Hematol & Stem Cell Transplantat, West German Canc Ctr, Essen, Germany

[2] Haugesund Hosp, Dept Res & Innovat, Haugesund, Norway

[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[4] Univ Coll London Hosp NHS Fdn Trust, UCLH Ctr Waldenstroms Macroglobulinemia & Related, London, England

[5] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria

[6] UPEC, Henri Mondor Univ Hosp, Assistance Publ Hop Paris, Creteil, France

[7] USC, Keck Sch Med, Jane Anne Nohl Div Hematol, Dept Med, Los Angeles, CA USA

[8] Ishikawa Prefectural Cent Hosp, Dept Hematol, Kanazawa, Japan

[9] Osaka Univ, Osaka, Japan

[10] Amsterdam UMC, Amsterdam, Netherlands

[11] Sanquin, Dept Hematol, Amsterdam, Netherlands

[12] Sanofi, Cambridge, England

[13] IQVIA, Bangalore, Karnataka, India

[14] Sanofi, Warsaw, Poland

[15] MedStar Georgetown Univ Hosp, Div Hematol, Washington, DC USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V575

引用

页码：172 / 173

页数：2

共 50 条

[21] Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program
Gelbenegger, Georg
Schoergenhofer, Christian
Derhaschnig, Ulla
Buchtele, Nina
Sillaber, Christian
Fillitz, Michael
Schenk, Thomas M.
D'Sa, Shirley
Cartwright, Ronwyn
Gilbert, James C.
Jilma, Bernd
Jaeger, Ulrich
[J]. BLOOD ADVANCES, 2020, 4 (06) : 997 - 1005
[22] Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CASCADE)
Jilma, Bernd
Roman, Eloy
Ueda, Yasutaka
Mappa, Silvia
Szamosi, Johan
Savage, Jessica
Roeth, Alexander
[J]. BLOOD, 2022, 140 : 5326 - 5327
[23] Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study
Kinoshita, Yoshikazu
Sakurai, Yuuichi
Takabayashi, Nobuyoshi
Kudou, Kentaro
Araki, Takahiro
Miyagi, Takuya
Iwakiri, Katsuhiko
Ashida, Kiyoshi
[J]. CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2019, 10
[24] Chronic Inhibition of Complement C1s By TNT009 Produces Sustained, Complete Remission in Patients with Severe, Transfusion-Dependent Cold Agglutinin Disease (CAD)
Jilma, Bernd
Gilbert, James C.
Panicker, Sandip
Parry, Graham C.
Fillitz, Michael
Thomas, Schenk
Sillaber, Christian
Bartko, Johann
Jaeger, Ulrich
[J]. BLOOD, 2016, 128 (22)
[25] Efficacy and safety of apremilast for the treatment of Japanese patients with palmoplantar pustulosis: Results from a phase 2, randomized, placebo-controlled study
Terui, Tadashi
Okubo, Yukari
Kobayashi, Satomi
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB50 - AB50
[26] Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study
Terui, Tadashi
Okubo, Yukari
Kobayashi, Satomi
Sano, Shigetoshi
Morita, Akimichi
Imafuku, Shinichi
Tada, Yayoi
Abe, Masatoshi
Yaguchi, Masafumi
Uehara, Natsuka
Handa, Takahiro
Tanaka, Masayuki
Zhang, Wendy
Paris, Maria
Murakami, Masamoto
[J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (05) : 837 - 847
[27] Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study
Tadashi Terui
Yukari Okubo
Satomi Kobayashi
Shigetoshi Sano
Akimichi Morita
Shinichi Imafuku
Yayoi Tada
Masatoshi Abe
Masafumi Yaguchi
Natsuka Uehara
Takahiro Handa
Masayuki Tanaka
Wendy Zhang
Maria Paris
Masamoto Murakami
[J]. American Journal of Clinical Dermatology, 2023, 24 : 837 - 847
[28] Efficacy and Safety of Filgotinib as Induction and Maintenance Therapy for Crohn's Disease: Results From the Phase 3 Randomized, Double-Blind, Placebo-Controlled DIVERSITY1 Study
Vermeire, Severine
Rubin, David T.
Watanabe, Mamoru
Schreiber, Stefan
Mehta, Rajiv
Roblin, Xavier
Genovese, Mark C.
Masior, Tomasz
Barron, Rahul
Le Brun, Franck-Olivier
Danese, Silvio
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S673 - S675
[29] Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
Takeshima, Takao
Sakai, Fumihiko
Hirata, Koichi
Imai, Noboru
Matsumori, Yasuhiko
Yoshida, Ryuji
Peng, Cheng
Cheng, Sunfa
Mikol, Daniel D.
[J]. HEADACHE, 2021, 61 (06): : 927 - 935
[30] Efficacy and safety of adalimumab in Chinese patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, placebo-controlled, double-blind Study
Zhang, Jianzhong
Gu, Jun
Zheng, Jie
Zheng, Min
Wang, Gang
Gu, Yihua
Okun, Martin
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB232 - AB232

← 1 2 3 4 5 →